Site icon Market Globalist

Here are all the latest developments about Summit Therapeutics Inc (SMMT) stock

DNAY Stock

DNAY Stock

Summit Therapeutics Inc. (SMMT) shares rose 17.01% to trade at $6.33 in after-market on Friday, May 14, 2021.  Earlier, SMMT’s stock lost 0.37% to close Friday’s normal trading session at $5.41. SMMT shares have risen 60.06% over the last 12 months, and they have moved down 7.04% in the past week. Over the past three months, the stock has lost 29.74%, while over the past six months, it has added 45.82%.

Let’s see what’s going on with the company?

Discover Tomorrow's Stocks Today!

When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.

Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored

Closing of $75 million rights offering

On May 12, 2021, Summit Therapeutics Inc closed its fully subscribed rights offering and the associated results.

The rights offering resulted in the sale of 14,312,976 shares of the Company’s common stock, par value $0.01 at $5.24 per share. the company will get gross proceeds of $75 million from the offer.

Read More

Revealing recent scientific updates

On May 5, 2021, Summit Therapeutics Inc published the scientific and related content on the company’s corporate website for our investigational drug, ridinilazole, which is currently enrolling patients in its Phase 3 clinical trials.

Financial results announcement

On March 17, 2021, Summit Therapeutics Inc released its financial results for the fourth quarter and the full-year ended December 31, 2020.

Q4 2020 financial highlights

  • SMMT revenue for Q4 2020 was $185 million compared to 161 million in the same quarter in 2019.
  • Total operating expenses were $16.1 million in Q4 2020 compared to $14.9 million in Q4 2019.
  • Operating loss was $11.6 million in Q4 2020 compared to $9.05 million in Q4 2019.
  • Summit Therapeutics suffered a net loss of $ 13.5 million or a basic or diluted loss per share of $0.18 in Q4 2020 compared to $11.9 million or a basic or diluted loss per share of $0.34 in Q4 2019. 

FY 2020 financial highlights

  • SMMT revenue for the FY2020 was $860 million compared to 743 million in FY 2019.
  • Total operating expenses were $73.4 million in FY 2020 compared to $51.1 million in FY 2019.
  • Operating loss was $53.2 million in FY 2020 compared to $27.4 million in FY 2019.
  • Summit Therapeutics suffered a net loss of $ 52.7 million or a basic or diluted loss per share of $0.76 in FY 2020 compared to $29.13 million or a basic or diluted loss per share of $0.89 in FY 2019.
  • As of December 31, 2020, SMMT had cash and cash equivalents of $66.4 million compared to $63.8 million on December 31, 2019.

Conclusion

We could not find any recent news to justify its flip on Friday and it is hard to predict how SMMT stock will perform in the coming days.